SPECT imaging of the dopamine transporter with [123I]-β-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction
Identifieur interne : 002F68 ( Main/Corpus ); précédent : 002F67; suivant : 002F69SPECT imaging of the dopamine transporter with [123I]-β-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction
Auteurs : Ryuji Sakakibara ; Hitoshi Shinotoh ; Tomoyuki Uchiyama ; Mitsuharu Yoshiyama ; Takamichi Hattori ; Tomonori YamanishiSource :
- Journal of the Neurological Sciences [ 0022-510X ] ; 2001.
Abstract
We studied a correlation of urinary dysfunction with nigrostriatal dopaminergic deficit in Parkinson's disease (PD) by single-photon emission computed tomography (SPECT) imaging of dopamine transporter with [123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane (β-CIT). Eleven patients were enrolled in the study, including four men and seven women, with a mean age of 64 years. Seven patients had urinary symptoms 1–5 years after the onset of motor disorder, which included nighttime frequency in six, urinary retardation in four, daytime frequency in one and urge urinary incontinence in one. Using a SPECT camera, the ratio specific to nondisplaceable [123I]-β-CIT uptake, designated as ‘striatal V3’ was obtained in the caudate, anterior and posterior putamen 24 h after the tracer injection. The striatal V3 was compared in patients with and without urinary dysfunction, and between men and women, using unpaired Student's t-test. Correlation of motor dysfunction and duration of illness with urinary dysfunction, was also analyzed. In the patients, there was a reduction of [123I]-β-CIT binding in the striatum on both sides, particularly in the putamen contralateral to the affected body side. The striatal V3 of the caudate (p<0.01, Rt; p<0.05, Lt), anterior putamen (p<0.05, Rt) and posterior putamen (p<0.05, Rt) in patients with urinary dysfunction was significantly reduced than those without urinary dysfunction. No sex difference was seen in reduction of [123I]-β-CIT binding. Urinary dysfunction in PD was more common in patients with higher Unified Parkinson's Disease Rating Scale (UPDRS) score, higher Hoehn–Yahr grade, but not in those with longer duration of disease, although there was no statistical significance. It is likely that our results reflect the association of urinary dysfunction and degeneration of the nigrostriatal dopaminergic cells in PD.
Url:
DOI: 10.1016/S0022-510X(01)00521-4
Links to Exploration step
ISTEX:546E8DEABDD7050FFF48BD8706DF78E27F41010FLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>SPECT imaging of the dopamine transporter with [123I]-β-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction</title><author><name sortKey="Sakakibara, Ryuji" sort="Sakakibara, Ryuji" uniqKey="Sakakibara R" first="Ryuji" last="Sakakibara">Ryuji Sakakibara</name><affiliation><mods:affiliation>E-mail: sakaki@med.m.chiba-u.ac.jp</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, Chiba University School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan</mods:affiliation></affiliation></author><author><name sortKey="Shinotoh, Hitoshi" sort="Shinotoh, Hitoshi" uniqKey="Shinotoh H" first="Hitoshi" last="Shinotoh">Hitoshi Shinotoh</name><affiliation><mods:affiliation>Department of Neurology, Chiba University School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan</mods:affiliation></affiliation></author><author><name sortKey="Uchiyama, Tomoyuki" sort="Uchiyama, Tomoyuki" uniqKey="Uchiyama T" first="Tomoyuki" last="Uchiyama">Tomoyuki Uchiyama</name><affiliation><mods:affiliation>Department of Neurology, Chiba University School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan</mods:affiliation></affiliation></author><author><name sortKey="Yoshiyama, Mitsuharu" sort="Yoshiyama, Mitsuharu" uniqKey="Yoshiyama M" first="Mitsuharu" last="Yoshiyama">Mitsuharu Yoshiyama</name><affiliation><mods:affiliation>Department of Neurology, Chiba University School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan</mods:affiliation></affiliation></author><author><name sortKey="Hattori, Takamichi" sort="Hattori, Takamichi" uniqKey="Hattori T" first="Takamichi" last="Hattori">Takamichi Hattori</name><affiliation><mods:affiliation>Department of Neurology, Chiba University School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan</mods:affiliation></affiliation></author><author><name sortKey="Yamanishi, Tomonori" sort="Yamanishi, Tomonori" uniqKey="Yamanishi T" first="Tomonori" last="Yamanishi">Tomonori Yamanishi</name><affiliation><mods:affiliation>Department of Urology, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:546E8DEABDD7050FFF48BD8706DF78E27F41010F</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1016/S0022-510X(01)00521-4</idno><idno type="url">https://api.istex.fr/document/546E8DEABDD7050FFF48BD8706DF78E27F41010F/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002F68</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">SPECT imaging of the dopamine transporter with [123I]-β-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction</title><author><name sortKey="Sakakibara, Ryuji" sort="Sakakibara, Ryuji" uniqKey="Sakakibara R" first="Ryuji" last="Sakakibara">Ryuji Sakakibara</name><affiliation><mods:affiliation>E-mail: sakaki@med.m.chiba-u.ac.jp</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, Chiba University School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan</mods:affiliation></affiliation></author><author><name sortKey="Shinotoh, Hitoshi" sort="Shinotoh, Hitoshi" uniqKey="Shinotoh H" first="Hitoshi" last="Shinotoh">Hitoshi Shinotoh</name><affiliation><mods:affiliation>Department of Neurology, Chiba University School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan</mods:affiliation></affiliation></author><author><name sortKey="Uchiyama, Tomoyuki" sort="Uchiyama, Tomoyuki" uniqKey="Uchiyama T" first="Tomoyuki" last="Uchiyama">Tomoyuki Uchiyama</name><affiliation><mods:affiliation>Department of Neurology, Chiba University School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan</mods:affiliation></affiliation></author><author><name sortKey="Yoshiyama, Mitsuharu" sort="Yoshiyama, Mitsuharu" uniqKey="Yoshiyama M" first="Mitsuharu" last="Yoshiyama">Mitsuharu Yoshiyama</name><affiliation><mods:affiliation>Department of Neurology, Chiba University School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan</mods:affiliation></affiliation></author><author><name sortKey="Hattori, Takamichi" sort="Hattori, Takamichi" uniqKey="Hattori T" first="Takamichi" last="Hattori">Takamichi Hattori</name><affiliation><mods:affiliation>Department of Neurology, Chiba University School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan</mods:affiliation></affiliation></author><author><name sortKey="Yamanishi, Tomonori" sort="Yamanishi, Tomonori" uniqKey="Yamanishi T" first="Tomonori" last="Yamanishi">Tomonori Yamanishi</name><affiliation><mods:affiliation>Department of Urology, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of the Neurological Sciences</title><title level="j" type="abbrev">JNS</title><idno type="ISSN">0022-510X</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2001">2001</date><biblScope unit="volume">187</biblScope><biblScope unit="issue">1–2</biblScope><biblScope unit="page" from="55">55</biblScope><biblScope unit="page" to="59">59</biblScope></imprint><idno type="ISSN">0022-510X</idno></series><idno type="istex">546E8DEABDD7050FFF48BD8706DF78E27F41010F</idno><idno type="DOI">10.1016/S0022-510X(01)00521-4</idno><idno type="PII">S0022-510X(01)00521-4</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-510X</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We studied a correlation of urinary dysfunction with nigrostriatal dopaminergic deficit in Parkinson's disease (PD) by single-photon emission computed tomography (SPECT) imaging of dopamine transporter with [123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane (β-CIT). Eleven patients were enrolled in the study, including four men and seven women, with a mean age of 64 years. Seven patients had urinary symptoms 1–5 years after the onset of motor disorder, which included nighttime frequency in six, urinary retardation in four, daytime frequency in one and urge urinary incontinence in one. Using a SPECT camera, the ratio specific to nondisplaceable [123I]-β-CIT uptake, designated as ‘striatal V3’ was obtained in the caudate, anterior and posterior putamen 24 h after the tracer injection. The striatal V3 was compared in patients with and without urinary dysfunction, and between men and women, using unpaired Student's t-test. Correlation of motor dysfunction and duration of illness with urinary dysfunction, was also analyzed. In the patients, there was a reduction of [123I]-β-CIT binding in the striatum on both sides, particularly in the putamen contralateral to the affected body side. The striatal V3 of the caudate (p<0.01, Rt; p<0.05, Lt), anterior putamen (p<0.05, Rt) and posterior putamen (p<0.05, Rt) in patients with urinary dysfunction was significantly reduced than those without urinary dysfunction. No sex difference was seen in reduction of [123I]-β-CIT binding. Urinary dysfunction in PD was more common in patients with higher Unified Parkinson's Disease Rating Scale (UPDRS) score, higher Hoehn–Yahr grade, but not in those with longer duration of disease, although there was no statistical significance. It is likely that our results reflect the association of urinary dysfunction and degeneration of the nigrostriatal dopaminergic cells in PD.</div></front></TEI><istex><corpusName>elsevier</corpusName><author><json:item><name>Ryuji Sakakibara</name><affiliations><json:string>E-mail: sakaki@med.m.chiba-u.ac.jp</json:string><json:string>Department of Neurology, Chiba University School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan</json:string></affiliations></json:item><json:item><name>Hitoshi Shinotoh</name><affiliations><json:string>Department of Neurology, Chiba University School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan</json:string></affiliations></json:item><json:item><name>Tomoyuki Uchiyama</name><affiliations><json:string>Department of Neurology, Chiba University School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan</json:string></affiliations></json:item><json:item><name>Mitsuharu Yoshiyama</name><affiliations><json:string>Department of Neurology, Chiba University School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan</json:string></affiliations></json:item><json:item><name>Takamichi Hattori</name><affiliations><json:string>Department of Neurology, Chiba University School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan</json:string></affiliations></json:item><json:item><name>Tomonori Yamanishi</name><affiliations><json:string>Department of Urology, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Urinary dysfunction</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Dopamine transporter</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Single-photon emission computed tomography (SPECT)</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>[123I]-β-CIT</value></json:item></subject><language><json:string>eng</json:string></language><abstract>We studied a correlation of urinary dysfunction with nigrostriatal dopaminergic deficit in Parkinson's disease (PD) by single-photon emission computed tomography (SPECT) imaging of dopamine transporter with [123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane (β-CIT). Eleven patients were enrolled in the study, including four men and seven women, with a mean age of 64 years. Seven patients had urinary symptoms 1–5 years after the onset of motor disorder, which included nighttime frequency in six, urinary retardation in four, daytime frequency in one and urge urinary incontinence in one. Using a SPECT camera, the ratio specific to nondisplaceable [123I]-β-CIT uptake, designated as ‘striatal V3’ was obtained in the caudate, anterior and posterior putamen 24 h after the tracer injection. The striatal V3 was compared in patients with and without urinary dysfunction, and between men and women, using unpaired Student's t-test. Correlation of motor dysfunction and duration of illness with urinary dysfunction, was also analyzed. In the patients, there was a reduction of [123I]-β-CIT binding in the striatum on both sides, particularly in the putamen contralateral to the affected body side. The striatal V3 of the caudate (p>0.01, Rt; p>0.05, Lt), anterior putamen (p>0.05, Rt) and posterior putamen (p>0.05, Rt) in patients with urinary dysfunction was significantly reduced than those without urinary dysfunction. No sex difference was seen in reduction of [123I]-β-CIT binding. Urinary dysfunction in PD was more common in patients with higher Unified Parkinson's Disease Rating Scale (UPDRS) score, higher Hoehn–Yahr grade, but not in those with longer duration of disease, although there was no statistical significance. It is likely that our results reflect the association of urinary dysfunction and degeneration of the nigrostriatal dopaminergic cells in PD.</abstract><qualityIndicators><score>6.081</score><pdfVersion>1.2</pdfVersion><pdfPageSize>595 x 758 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>1870</abstractCharCount><pdfWordCount>3081</pdfWordCount><pdfCharCount>20218</pdfCharCount><pdfPageCount>5</pdfPageCount><abstractWordCount>271</abstractWordCount></qualityIndicators><title>SPECT imaging of the dopamine transporter with [123I]-β-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction</title><pii><json:string>S0022-510X(01)00521-4</json:string></pii><genre><json:string>research-article</json:string></genre><serie><volume>vol. 2</volume><editor><json:item><name>S. Fahn</name></json:item><json:item><name>C.D. Marsden</name></json:item><json:item><name>D.B. Calne</name></json:item><json:item><name>A. Lieberman</name></json:item></editor><pages><last>163</last><first>153</first></pages><genre></genre><language><json:string>unknown</json:string></language><title>Recent developments in Parkinson's disease</title></serie><host><volume>187</volume><pii><json:string>S0022-510X(00)X0114-1</json:string></pii><pages><last>59</last><first>55</first></pages><issn><json:string>0022-510X</json:string></issn><issue>1–2</issue><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><title>Journal of the Neurological Sciences</title><publicationDate>2001</publicationDate></host><categories><wos><json:string>CLINICAL NEUROLOGY</json:string><json:string>NEUROIMAGING</json:string><json:string>NEUROSCIENCES</json:string></wos></categories><publicationDate>2001</publicationDate><copyrightDate>2001</copyrightDate><doi><json:string>10.1016/S0022-510X(01)00521-4</json:string></doi><id>546E8DEABDD7050FFF48BD8706DF78E27F41010F</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/546E8DEABDD7050FFF48BD8706DF78E27F41010F/fulltext/pdf</uri></json:item><json:item><original>true</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/546E8DEABDD7050FFF48BD8706DF78E27F41010F/fulltext/txt</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/546E8DEABDD7050FFF48BD8706DF78E27F41010F/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/546E8DEABDD7050FFF48BD8706DF78E27F41010F/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a">SPECT imaging of the dopamine transporter with [123I]-β-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>ELSEVIER</publisher><availability><p>ELSEVIER</p></availability><date>2001</date></publicationStmt><notesStmt><note type="content">Fig. 1: Arrangement of region of interest (ROI) in the SPECT study. Each ROI was placed for the caudate, anterior putamen and posterior putamen on both hemispheres. R←→L.</note><note type="content">Fig. 2: Striatal V3 of patients with (u+) and without (u−) urinary dysfunction. The striatal V3 of the caudate (p<0.01, Rt; p<0.05, Lt), anterior putamen (p<0.05, Rt) and posterior putamen (p<0.05, Rt) in patients with urinary dysfunction was significantly reduced than those without urinary dysfunction. L: left, R: right, CD: caudate, AP: anterior putamen, PP: posterior putamen.</note><note type="content">Table 1: Patients</note><note type="content">Table 2: Striatal V3 of men and women with urinary dysfunction No sex difference was seen in the reduction of β-CIT binding in patients with urinary dysfunction.</note><note type="content">Table 3: Correlation between duration of disease, motor dysfunction and urinary dysfunction Urinary dysfunction was more common in patients with higher UPDRS total score and higher Hoehn–Yahr grade, but not in those with longer duration of the disease, although there was no statistical significance.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">SPECT imaging of the dopamine transporter with [123I]-β-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction</title><author><persName><forename type="first">Ryuji</forename><surname>Sakakibara</surname></persName><email>sakaki@med.m.chiba-u.ac.jp</email><note type="correspondence"><p>Corresponding author. Tel.: +81-43-226-2129; fax: +81-43-226-2160</p></note><affiliation>Department of Neurology, Chiba University School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan</affiliation></author><author><persName><forename type="first">Hitoshi</forename><surname>Shinotoh</surname></persName><affiliation>Department of Neurology, Chiba University School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan</affiliation></author><author><persName><forename type="first">Tomoyuki</forename><surname>Uchiyama</surname></persName><affiliation>Department of Neurology, Chiba University School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan</affiliation></author><author><persName><forename type="first">Mitsuharu</forename><surname>Yoshiyama</surname></persName><affiliation>Department of Neurology, Chiba University School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan</affiliation></author><author><persName><forename type="first">Takamichi</forename><surname>Hattori</surname></persName><affiliation>Department of Neurology, Chiba University School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan</affiliation></author><author><persName><forename type="first">Tomonori</forename><surname>Yamanishi</surname></persName><affiliation>Department of Urology, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan</affiliation></author></analytic><monogr><title level="j">Journal of the Neurological Sciences</title><title level="j" type="abbrev">JNS</title><idno type="pISSN">0022-510X</idno><idno type="PII">S0022-510X(00)X0114-1</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2001"></date><biblScope unit="volume">187</biblScope><biblScope unit="issue">1–2</biblScope><biblScope unit="page" from="55">55</biblScope><biblScope unit="page" to="59">59</biblScope></imprint></monogr><idno type="istex">546E8DEABDD7050FFF48BD8706DF78E27F41010F</idno><idno type="DOI">10.1016/S0022-510X(01)00521-4</idno><idno type="PII">S0022-510X(01)00521-4</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2001</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>We studied a correlation of urinary dysfunction with nigrostriatal dopaminergic deficit in Parkinson's disease (PD) by single-photon emission computed tomography (SPECT) imaging of dopamine transporter with [123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane (β-CIT). Eleven patients were enrolled in the study, including four men and seven women, with a mean age of 64 years. Seven patients had urinary symptoms 1–5 years after the onset of motor disorder, which included nighttime frequency in six, urinary retardation in four, daytime frequency in one and urge urinary incontinence in one. Using a SPECT camera, the ratio specific to nondisplaceable [123I]-β-CIT uptake, designated as ‘striatal V3’ was obtained in the caudate, anterior and posterior putamen 24 h after the tracer injection. The striatal V3 was compared in patients with and without urinary dysfunction, and between men and women, using unpaired Student's t-test. Correlation of motor dysfunction and duration of illness with urinary dysfunction, was also analyzed. In the patients, there was a reduction of [123I]-β-CIT binding in the striatum on both sides, particularly in the putamen contralateral to the affected body side. The striatal V3 of the caudate (p<0.01, Rt; p<0.05, Lt), anterior putamen (p<0.05, Rt) and posterior putamen (p<0.05, Rt) in patients with urinary dysfunction was significantly reduced than those without urinary dysfunction. No sex difference was seen in reduction of [123I]-β-CIT binding. Urinary dysfunction in PD was more common in patients with higher Unified Parkinson's Disease Rating Scale (UPDRS) score, higher Hoehn–Yahr grade, but not in those with longer duration of disease, although there was no statistical significance. It is likely that our results reflect the association of urinary dysfunction and degeneration of the nigrostriatal dopaminergic cells in PD.</p></abstract><textClass><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>Urinary dysfunction</term></item><item><term>Dopamine transporter</term></item><item><term>Single-photon emission computed tomography (SPECT)</term></item><item><term>[123I]-β-CIT</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2001-03-26">Registration</change><change when="2001-03-26">Modified</change><change when="2001">Published</change></revisionDesc></teiHeader></istex:fulltextTEI></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: ce:floats; body; tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"><istex:entity SYSTEM="gr1" NDATA="IMAGE" name="gr1"></istex:entity><istex:entity SYSTEM="gr2" NDATA="IMAGE" name="gr2"></istex:entity></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla"><item-info><jid>JNS</jid><aid>6619</aid><ce:pii>S0022-510X(01)00521-4</ce:pii><ce:doi>10.1016/S0022-510X(01)00521-4</ce:doi><ce:copyright type="full-transfer" year="2001">Elsevier Science B.V.</ce:copyright></item-info><head><ce:title>SPECT imaging of the dopamine transporter with [<ce:sup loc="pre">123</ce:sup>I]-β-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction</ce:title><ce:author-group><ce:author><ce:given-name>Ryuji</ce:given-name><ce:surname>Sakakibara</ce:surname><ce:cross-ref refid="COR1">*</ce:cross-ref><ce:cross-ref refid="AFF1"><ce:sup>a</ce:sup></ce:cross-ref><ce:e-address>sakaki@med.m.chiba-u.ac.jp</ce:e-address></ce:author><ce:author><ce:given-name>Hitoshi</ce:given-name><ce:surname>Shinotoh</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>a</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Tomoyuki</ce:given-name><ce:surname>Uchiyama</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>a</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Mitsuharu</ce:given-name><ce:surname>Yoshiyama</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>a</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Takamichi</ce:given-name><ce:surname>Hattori</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>a</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Tomonori</ce:given-name><ce:surname>Yamanishi</ce:surname><ce:cross-ref refid="AFF2"><ce:sup>b</ce:sup></ce:cross-ref></ce:author><ce:affiliation id="AFF1"><ce:label>a</ce:label><ce:textfn>Department of Neurology, Chiba University School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan</ce:textfn></ce:affiliation><ce:affiliation id="AFF2"><ce:label>b</ce:label><ce:textfn>Department of Urology, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan</ce:textfn></ce:affiliation><ce:correspondence id="COR1"><ce:label>*</ce:label><ce:text>Corresponding author. Tel.: +81-43-226-2129; fax: +81-43-226-2160</ce:text></ce:correspondence></ce:author-group><ce:date-received day="25" month="7" year="2000"></ce:date-received><ce:date-revised day="26" month="3" year="2001"></ce:date-revised><ce:date-accepted day="26" month="3" year="2001"></ce:date-accepted><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>We studied a correlation of urinary dysfunction with nigrostriatal dopaminergic deficit in Parkinson's disease (PD) by single-photon emission computed tomography (SPECT) imaging of dopamine transporter with [<ce:sup loc="pre">123</ce:sup>I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane (β-CIT). Eleven patients were enrolled in the study, including four men and seven women, with a mean age of 64 years. Seven patients had urinary symptoms 1–5 years after the onset of motor disorder, which included nighttime frequency in six, urinary retardation in four, daytime frequency in one and urge urinary incontinence in one. Using a SPECT camera, the ratio specific to nondisplaceable [<ce:sup loc="pre">123</ce:sup>I]-β-CIT uptake, designated as ‘striatal V3’ was obtained in the caudate, anterior and posterior putamen 24 h after the tracer injection. The striatal V3 was compared in patients with and without urinary dysfunction, and between men and women, using unpaired Student's <ce:italic>t</ce:italic>-test. Correlation of motor dysfunction and duration of illness with urinary dysfunction, was also analyzed. In the patients, there was a reduction of [<ce:sup loc="pre">123</ce:sup>I]-β-CIT binding in the striatum on both sides, particularly in the putamen contralateral to the affected body side. The striatal V3 of the caudate (<ce:italic>p</ce:italic><0.01, Rt; <ce:italic>p</ce:italic><0.05, Lt), anterior putamen (<ce:italic>p</ce:italic><0.05, Rt) and posterior putamen (<ce:italic>p</ce:italic><0.05, Rt) in patients with urinary dysfunction was significantly reduced than those without urinary dysfunction. No sex difference was seen in reduction of [<ce:sup loc="pre">123</ce:sup>I]-β-CIT binding. Urinary dysfunction in PD was more common in patients with higher Unified Parkinson's Disease Rating Scale (UPDRS) score, higher Hoehn–Yahr grade, but not in those with longer duration of disease, although there was no statistical significance. It is likely that our results reflect the association of urinary dysfunction and degeneration of the nigrostriatal dopaminergic cells in PD.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords class="keyword"><ce:section-title>Keywords</ce:section-title><ce:keyword><ce:text>Parkinson's disease</ce:text></ce:keyword><ce:keyword><ce:text>Urinary dysfunction</ce:text></ce:keyword><ce:keyword><ce:text>Dopamine transporter</ce:text></ce:keyword><ce:keyword><ce:text>Single-photon emission computed tomography (SPECT)</ce:text></ce:keyword><ce:keyword><ce:text>[<ce:sup loc="pre">123</ce:sup>I]-β-CIT</ce:text></ce:keyword></ce:keywords></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>SPECT imaging of the dopamine transporter with [123I]-β-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>SPECT imaging of the dopamine transporter with [</title></titleInfo><name type="personal"><namePart type="given">Ryuji</namePart><namePart type="family">Sakakibara</namePart><affiliation>E-mail: sakaki@med.m.chiba-u.ac.jp</affiliation><affiliation>Department of Neurology, Chiba University School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan</affiliation><description>Corresponding author. Tel.: +81-43-226-2129; fax: +81-43-226-2160</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Hitoshi</namePart><namePart type="family">Shinotoh</namePart><affiliation>Department of Neurology, Chiba University School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Tomoyuki</namePart><namePart type="family">Uchiyama</namePart><affiliation>Department of Neurology, Chiba University School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Mitsuharu</namePart><namePart type="family">Yoshiyama</namePart><affiliation>Department of Neurology, Chiba University School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Takamichi</namePart><namePart type="family">Hattori</namePart><affiliation>Department of Neurology, Chiba University School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Tomonori</namePart><namePart type="family">Yamanishi</namePart><affiliation>Department of Urology, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article"></genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">2001</dateIssued><dateValid encoding="w3cdtf">2001-03-26</dateValid><dateModified encoding="w3cdtf">2001-03-26</dateModified><copyrightDate encoding="w3cdtf">2001</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">We studied a correlation of urinary dysfunction with nigrostriatal dopaminergic deficit in Parkinson's disease (PD) by single-photon emission computed tomography (SPECT) imaging of dopamine transporter with [123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane (β-CIT). Eleven patients were enrolled in the study, including four men and seven women, with a mean age of 64 years. Seven patients had urinary symptoms 1–5 years after the onset of motor disorder, which included nighttime frequency in six, urinary retardation in four, daytime frequency in one and urge urinary incontinence in one. Using a SPECT camera, the ratio specific to nondisplaceable [123I]-β-CIT uptake, designated as ‘striatal V3’ was obtained in the caudate, anterior and posterior putamen 24 h after the tracer injection. The striatal V3 was compared in patients with and without urinary dysfunction, and between men and women, using unpaired Student's t-test. Correlation of motor dysfunction and duration of illness with urinary dysfunction, was also analyzed. In the patients, there was a reduction of [123I]-β-CIT binding in the striatum on both sides, particularly in the putamen contralateral to the affected body side. The striatal V3 of the caudate (p<0.01, Rt; p<0.05, Lt), anterior putamen (p<0.05, Rt) and posterior putamen (p<0.05, Rt) in patients with urinary dysfunction was significantly reduced than those without urinary dysfunction. No sex difference was seen in reduction of [123I]-β-CIT binding. Urinary dysfunction in PD was more common in patients with higher Unified Parkinson's Disease Rating Scale (UPDRS) score, higher Hoehn–Yahr grade, but not in those with longer duration of disease, although there was no statistical significance. It is likely that our results reflect the association of urinary dysfunction and degeneration of the nigrostriatal dopaminergic cells in PD.</abstract><note type="content">Fig. 1: Arrangement of region of interest (ROI) in the SPECT study. Each ROI was placed for the caudate, anterior putamen and posterior putamen on both hemispheres. R←→L.</note><note type="content">Fig. 2: Striatal V3 of patients with (u+) and without (u−) urinary dysfunction. The striatal V3 of the caudate (p<0.01, Rt; p<0.05, Lt), anterior putamen (p<0.05, Rt) and posterior putamen (p<0.05, Rt) in patients with urinary dysfunction was significantly reduced than those without urinary dysfunction. L: left, R: right, CD: caudate, AP: anterior putamen, PP: posterior putamen.</note><note type="content">Table 1: Patients</note><note type="content">Table 2: Striatal V3 of men and women with urinary dysfunction No sex difference was seen in the reduction of β-CIT binding in patients with urinary dysfunction.</note><note type="content">Table 3: Correlation between duration of disease, motor dysfunction and urinary dysfunction Urinary dysfunction was more common in patients with higher UPDRS total score and higher Hoehn–Yahr grade, but not in those with longer duration of the disease, although there was no statistical significance.</note><subject><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>Urinary dysfunction</topic><topic>Dopamine transporter</topic><topic>Single-photon emission computed tomography (SPECT)</topic><topic>[123I]-β-CIT</topic></subject><relatedItem type="host"><titleInfo><title>Journal of the Neurological Sciences</title></titleInfo><titleInfo type="abbreviated"><title>JNS</title></titleInfo><genre type="Journal">journal</genre><originInfo><dateIssued encoding="w3cdtf">20010615</dateIssued></originInfo><identifier type="ISSN">0022-510X</identifier><identifier type="PII">S0022-510X(00)X0114-1</identifier><part><date>20010615</date><detail type="volume"><number>187</number><caption>vol.</caption></detail><detail type="issue"><number>1–2</number><caption>no.</caption></detail><extent unit="issue pages"><start>1</start><end>118</end></extent><extent unit="pages"><start>55</start><end>59</end></extent></part></relatedItem><identifier type="istex">546E8DEABDD7050FFF48BD8706DF78E27F41010F</identifier><identifier type="DOI">10.1016/S0022-510X(01)00521-4</identifier><identifier type="PII">S0022-510X(01)00521-4</identifier><accessCondition type="use and reproduction" contentType="">© 2001Elsevier Science B.V.</accessCondition><recordInfo><recordContentSource>ELSEVIER</recordContentSource><recordOrigin>Elsevier Science B.V., ©2001</recordOrigin></recordInfo></mods></metadata><enrichments><istex:catWosTEI uri="https://api.istex.fr/document/546E8DEABDD7050FFF48BD8706DF78E27F41010F/enrichments/catWos"><teiHeader><profileDesc><textClass><classCode scheme="WOS">CLINICAL NEUROLOGY</classCode><classCode scheme="WOS">NEUROIMAGING</classCode><classCode scheme="WOS">NEUROSCIENCES</classCode></textClass></profileDesc></teiHeader></istex:catWosTEI></enrichments></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F68 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 002F68 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:546E8DEABDD7050FFF48BD8706DF78E27F41010F
|texte= SPECT imaging of the dopamine transporter with [123I]-β-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction
}}
| This area was generated with Dilib version V0.6.23. |  |